Omnicell (OMCL) Projected to Post Earnings on Tuesday

Omnicell (NASDAQ:OMCL) is projected to release its Q1 2026 results before the market opens on Tuesday, April 28th. Analysts expect Omnicell to post earnings of $0.33 per share and revenue of $304.0060 million for the quarter. Omnicell has set its Q1 2026 guidance at 0.260-0.360 EPS and its FY 2026 guidance at 1.650-1.850 EPS. Individuals can find conference call details on the company’s upcoming Q1 2026 earning report page for the latest details on the call scheduled for Tuesday, April 28, 2026 at 8:30 AM ET.

Omnicell (NASDAQ:OMCL) last posted its earnings results on Thursday, February 5th. The company reported $0.40 earnings per share for the quarter, missing analysts’ consensus estimates of $0.47 by ($0.07). The company had revenue of $313.98 million for the quarter, compared to analysts’ expectations of $313.36 million. Omnicell had a return on equity of 3.00% and a net margin of 0.17%.The firm’s quarterly revenue was up 2.3% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.60 EPS. On average, analysts expect Omnicell to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Omnicell Stock Up 2.7%

Omnicell stock opened at $37.37 on Friday. Omnicell has a twelve month low of $22.66 and a twelve month high of $55.00. The business has a fifty day moving average of $36.83 and a two-hundred day moving average of $39.19. The company has a quick ratio of 1.22, a current ratio of 1.43 and a debt-to-equity ratio of 0.14. The firm has a market cap of $1.70 billion, a P/E ratio of 934.48, a P/E/G ratio of 1.30 and a beta of 0.85.

Analyst Upgrades and Downgrades

Several analysts have recently commented on OMCL shares. Bank of America upgraded Omnicell from a “neutral” rating to a “buy” rating and set a $70.00 price objective for the company in a report on Wednesday, February 4th. Wall Street Zen lowered Omnicell from a “buy” rating to a “hold” rating in a report on Saturday, February 7th. Wells Fargo & Company increased their price objective on Omnicell from $52.00 to $55.00 and gave the company an “overweight” rating in a report on Thursday. Weiss Ratings lowered Omnicell from a “hold (c-)” rating to a “sell (d)” rating in a report on Monday, March 2nd. Finally, Piper Sandler reiterated an “overweight” rating and set a $49.00 price objective (down from $63.00) on shares of Omnicell in a report on Friday, February 6th. Six analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $59.00.

Insider Transactions at Omnicell

In related news, EVP Corey J. Manley sold 7,405 shares of the firm’s stock in a transaction on Monday, March 16th. The stock was sold at an average price of $34.69, for a total value of $256,879.45. Following the completion of the transaction, the executive vice president owned 96,717 shares in the company, valued at $3,355,112.73. This trade represents a 7.11% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. 2.52% of the stock is owned by company insiders.

Hedge Funds Weigh In On Omnicell

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Dimensional Fund Advisors LP raised its stake in Omnicell by 9.1% in the 3rd quarter. Dimensional Fund Advisors LP now owns 2,364,068 shares of the company’s stock worth $71,985,000 after acquiring an additional 197,462 shares during the last quarter. Wellington Management Group LLP raised its stake in Omnicell by 156.4% in the 4th quarter. Wellington Management Group LLP now owns 2,075,362 shares of the company’s stock worth $94,014,000 after acquiring an additional 1,265,818 shares during the last quarter. Lazard Asset Management LLC raised its stake in Omnicell by 3.8% in the 2nd quarter. Lazard Asset Management LLC now owns 1,708,345 shares of the company’s stock worth $50,225,000 after acquiring an additional 62,733 shares during the last quarter. Geode Capital Management LLC raised its stake in Omnicell by 1.0% in the 4th quarter. Geode Capital Management LLC now owns 1,127,583 shares of the company’s stock worth $51,088,000 after acquiring an additional 11,424 shares during the last quarter. Finally, Millennium Management LLC purchased a new position in Omnicell in the 3rd quarter worth $25,625,000. Hedge funds and other institutional investors own 97.70% of the company’s stock.

Omnicell Company Profile

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.